« Back
39th Annual Meeting of the Society for Immunotherapy of Cancer
Nov 08 - Nov 10, 2024
Immatics will present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer.
Oral Presentations
Date: November 8, 2024
Time: 3:50 PM CST
Title: ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients
Presenter: Martin Wermke, M.D.
Date: November 9, 2024
Time: 12:30 PM CST
Title: Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME
Presenter: Dejka M. Araujo, M.D.
Poster Presentations
Date: November 8, 2024
Poster Number: 355
Title: An approach to bridging starting materials to monitor T cell persistence in adoptive T cell therapy
Presenter: Jourdan Andersson, Ph.D.
Date: November 9, 2024
Poster Number: 226
Title: An effective donor screening program for manufacturing of allogeneic γδ T cell products
Presenter: Inbar Azoulay Alfaguter, Ph.D.
Date: November 9, 2024
Poster Number: 228
Title: Optimizing and streamlining the manufacturing of Vγ9Vδ2 γδ T cells for allogeneic therapy
Presenter: Pooja Mehta, Ph.D.
Date: November 9, 2024
Abstract Number: 360
Title: Combination of a TCR-engineered autologous PRAME-targeting T cell therapy with a PRAME-encoding mRNA for the treatment of solid tumors
Presenter: Fabian Brunk, Ph.D.
Date: November 9, 2024
Poster Number: 372
Title: TCR-engineered T cells exhibit enhanced persistence and serial killing ability when armored with membrane-bound IL-15
Presenter: Justin Gunesch, Ph.D.
Abstract: Full abstracts will be available on November 5, 2024, at 9:00 am EST in the JITC Supplement.
For more information about the presentation, read the full press release: https://investors.immatics.com/news-releases/news-release-details/immatics-announces-upcoming-oral-and-poster-presentations
Location